Impact of delaying PCV20 implementation in France's pediatric national immunization program: A population-based

Johnna Perdrizet1, Emmanuelle Blanc2, Jessica Y El Khoury2

  • 1Pfizer Canada, Kirkland, Quebec, Canada.

PubMed
Summary

Delaying the introduction of pneumococcal conjugate vaccine 20 (PCV20) in France could lead to thousands of preventable pneumococcal disease cases and deaths. Early PCV20 implementation offers significant public health and economic benefits.